Pfizer, Astellas Win FDA Priority Review

Pfizer and Astellas have received a priority review from the FDA for their drug Padcev, indicated for bladder cancer treatment. This designation, in conjunction with Merck's Keytruda, suggests a potentially accelerated path for regulatory approval. Priority review is granted to medicines that may offer significant improvements in the treatment, diagnosis, or prevention of serious conditions compared to available options. This news could positively impact the companies' oncology portfolios and patient access to advanced cancer therapies.